2019 Programme

The Reception | 18:30 - 21:00 | Wednesday 8th May

Venue to be confirmed


The Conference |  08:15 - 18:30 | Thursday 9th May 

8:15    Registration opens

9:00    Welcome 

 Mattias Johansson, Director, Ezenze Ltd, Anglonordic Conference Founder 

9:05     Keynote 

9:30   Investor Panel - What’s hot and what's simmering?

Panel discussion on Investment trends, chaired by Lisa Urquart, Editor, EP Vantage

Speakers include:

  •  Hakan Goker, Senior Investment Director, M Ventures
  •  Stephan Christgau, Senior Partner, Novo Seeds
  •  Roel Bulthuis, Managing Director, INKEF Capital

10:30   Coffee

11:00   Company Presentations

Biotech Investment Room and Technology Room


12:30 - 13:30    Networking Lunch


13:30    Technologies and treatments - What’s on the horizon?

 Panel Discussion, chaired by Lucie Ellis, Senior Editor Scrip, Pink Sheet, and In Vivo

Speakers include:

  •  Niall Martin, CEO, Artios Pharma
  •  Keith Blundy, CEO, Storm Therapeutics
  •  Ian Wilson, COO, ImaginAB

14:30    Company Presentations

Biotech Investment Room and Technology Room

15:45    Coffee

16:00    Challenges and opportunities for Women in European biotechnology 

Panel Discussion

Speakers include:

  •  Anne Marieke Ezendam, Senior Consultant, Optimum, ex-Fund Manager
  •  Renee Lecander, CEO, Calliditas

16:45   If I knew then what I know today

Panel Discussion chaired by Mike Ward, Chief Content Officer, Datamonitor Healthcare & Scrip Intelligence

Speakers include:

  • Anker Lundemose, CEO, Mission Therapeutics
  • Edwin Moses, Chairman, Serial entrepreneur and value creator

17.45    Conclusions

  • Hakan Goker, Senior Investment Director, M Ventures
  • Mary Clark, Managing Director, Optimum Strategic Communications

17.55 - 18:45   Drinks Reception

Hosted by Mattias Johansson, Director, Ezenze Ltd


1:1 meetings take place throughout the day and are pre-booked online. 

Partnering opens April 1st 2019


2019 Investors confirmed to date:

4BIO Capital, Albion Technology & General VCT, Arix Bioscience, Axilium Capital AB, Bayer AG, BioSeed Capital, Blenheim AI Health, Catapult Ventures, DeBere Capital Partners, FastVentures, Fresenius Medical Care Ventures GmbH, Gimv, Industrifonden, Inkef Capital BV, IPF Partners, Julz Co LLC, Kreos Capital, M Ventures, Masselos Family Office, MEDICXI, Momentum Biotech, National Institute for Health Research, NCL Technology Ventures, Norgine Ventures, Novo Ventures, Rothschild, Sunstone Life Science Ventures, UKI2S, Velocity Fund Partners, Vivanova.